Antitumour effect of the mitochondrial complex III inhibitor Atovaquone in combination with anti-PD-L1 therapy in mouse cancer models

Immune checkpoint blockade (ICB) provides effective and durable responses for several tumour types by unleashing an immune response directed against cancer cells. However, a substantial number of patients treated with ICB develop relapse or do not respond, which has been partly attributed to the imm...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cell death & disease Jg. 15; H. 1; S. 32 - 10
Hauptverfasser:	Rodriguez-Berriguete, Gonzalo, Puliyadi, Rathi, Machado, Nicole, Barberis, Alessandro, Prevo, Remko, McLaughlin, Martin, Buffa, Francesca M., Harrington, Kevin J., Higgins, Geoff S.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London Nature Publishing Group UK 11.01.2024 Springer Nature B.V Nature Publishing Group
Schlagworte:	14 14/34 14/63 631/67/2327 64/60 692/699/67 96/1 96/31 Animal models Animals Antibodies Atovaquone Atovaquone - pharmacology Atovaquone - therapeutic use B7-H1 Antigen Biochemistry Biomedical and Life Sciences Cancer CD8 antigen CD8-Positive T-Lymphocytes Cell Biology Cell Culture Colorectal cancer Colorectal carcinoma Electron Transport Complex III Humans Hypoxia Immune checkpoint inhibitors Immunological memory Immunology Immunotherapy - methods Life Sciences Lung cancer Lymphocytes T Memory cells Mice Neoplasms - drug therapy Oxygen consumption PD-L1 protein Toxicity Tumor Microenvironment Tumors
ISSN:	2041-4889, 2041-4889
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!